Dr. Matthew W. Doust, MD
Pain Medicine (Interventional Pain Medicine Physician)
17500 N Perimeter Dr Ste 100
Scottsdale, AZ 85255
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- State University of New York at Stony Brook, School of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 111
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: State University of New York at Stony Brook, School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Pain Medicine Physician primary
AZ license 29038
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Pain Center of Arizona PC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 111
- Services billed
- 1,155
- Patients’ average age
- 68
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 720 | 180 |
| Injection, dexamethasone sodium phosphate, 1 mg | 495 | 36 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 52 | 27 |
| Testing for presence of drug, by chemistry analyzers | 39 | 29 |
| Established patient office or other outpatient visit, 20-29 minutes | 29 | 22 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 20 | 12 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 18 | 11 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 17 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Scottsdale, AZ | 1,070 |
| Oxycodone Hcl Other prescribers in Scottsdale, AZ | 873 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Scottsdale, AZ | 781 |
| Gabapentin Other prescribers in Scottsdale, AZ | 669 |
| Morphine Sulfate Er (morphine sulfate) Other prescribers in Scottsdale, AZ | 401 |
| Pregabalin Other prescribers in Scottsdale, AZ | 306 |
| Tizanidine Hcl Other prescribers in Scottsdale, AZ | 282 |
| Cyclobenzaprine Hcl Other prescribers in Scottsdale, AZ | 232 |
| Tramadol Hcl Other prescribers in Scottsdale, AZ | 157 |
| Xtampza Er (oxycodone myristate) Other prescribers in Scottsdale, AZ | 139 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 9 payments worth $128 in total to this clinician.
| Valinor Pharma, LLC | $72.18 |
|---|---|
| Electronic Waveform Lab, Inc. | $30.45 |
| Boston Scientific Corporation | $25.39 |
| Food and Beverage | $128 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 6 companies. The companies reported $690,688 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A phase 1 randomized and phase 2 study to evaluate the safety tolerability immunogenicity and immunopersistence of a clostridioides difficile vaccine administered in a 2DOSE regimen with novel adjuvants in healthy adults
Pfizer Inc. - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age
ModernaTX, Inc. · Completed · NCT05127434 - A phase 3 randomized observerblinded study to evaluate the safety tolerability and immunogenicity of a combined modified rna vaccine candidate against COVID19 and influenza in healthy individuals
Pfizer Inc. - Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy
Eli Lilly and Company · Completed · NCT06568042 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT06603571 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Recruiting · NCT06143956 - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.